A Glimpse Into The Expert Outlook On GoodRx Holdings Through 4 Analysts
Benzinga Insights 8 months ago
Analyst Ratings
4 analysts have expressed a variety of opinions on GoodRx Holdings (NASDAQ:GDRX) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 0 | 2 | 1 | 0 |
| Last 30D | 0 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 1 | 0 | 1 | 0 | 0 |
| 3M Ago | 0 | 0 | 1 | 1 | 0 |
Analysts have set 12-month price targets for GoodRx Holdings, revealing an average target of $3.56, a high estimate of $4.50, and a low estimate of $2.75. A decline of 29.92% from the prior average price target is evident in the current average.
Interpreting Analyst Ratings: A Closer Look
The standing of GoodRx Holdings among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Glen Santangelo | Jefferies | Lowers | Hold | $2.75 | $5.25 |
| Daniel Grosslight | Citigroup | Lowers | Buy | $4.50 | $5.00 |
| Craig Hettenbach | Morgan Stanley | Lowers | Equal-Weight | $4.00 | $5.00 |
| Glen Santangelo | Barclays | Announces | Underweight | $3.00 | - |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to GoodRx Holdings. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of GoodRx Holdings compared to the broader market.
- Price Targets: Delving into movements, analysts provide estimates for the future value of GoodRx Holdings's stock. This analysis reveals shifts in analysts' expectations over time.
For valuable insights into GoodRx Holdings's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
Stay up to date on GoodRx Holdings analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Unveiling the Story Behind GoodRx Holdings
GoodRx Holdings Inc is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and provides access to negotiated prices through codes that can be used to save money on prescriptions across the United States. GoodRx generates revenue from core business from pharmacy benefit managers (PBMs) that manage formularies and prescription transactions including establishing pricing between consumers and pharmacies. It also offers various healthcare products and services, including pharma manufacturer solutions, subscriptions, and telehealth services.
Unraveling the Financial Story of GoodRx Holdings
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Positive Revenue Trend: Examining GoodRx Holdings's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 0.4% as of 30 September, 2025, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: GoodRx Holdings's net margin excels beyond industry benchmarks, reaching 0.57%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): GoodRx Holdings's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.18% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.08%, the company showcases effective utilization of assets.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 0.91, caution is advised due to increased financial risk.
The Basics of Analyst Ratings
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.